BetterLife Pharma (TSE:BETR)
:BETR
Want to see TSE:BETR full AI Analyst Report?
BETR Stock Chart & Stats
C$0.04
C$0.01(9.52%)
At close: 4:00 PM EST
C$0.04
C$0.01(9.52%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.10
Previous CloseN/A
Volume50.00
Average Volume (3M)121.96K
Market Cap
C$9.71M
Enterprise ValueC$10.01M
Total Cash (Recent Filing)C$12.57K
Total Debt (Recent Filing)C$905.00K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding161,787,020
10 Day Avg. Volume118,740
30 Day Avg. Volume121,961
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.75
Price to Sales (P/S)0.00
P/FCF Ratio-11.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused CNS PipelineA concentrated clinical-stage focus on neuropsychiatric and neurological disorders builds domain expertise and a coherent pipeline strategy. Over months this specialization supports durable competitive positioning for partnerships, targeted trial design, and licensing opportunities in a high unmet-need therapeutic area.
Improving Cash BurnMaterial reduction in operating cash outflows signals meaningful cost discipline and improved operational efficiency. Sustained lower burn increases runway and reduces short-term financing needs, making the funding profile more manageable over a 2–6 month horizon if the trend persists.
Low Debt / Lean Cost BaseA small employee base and modest reported debt limit fixed obligations and interest burden. This lean structure helps conserve cash and extend runway while the company advances clinical programs, supporting near-term operational sustainability versus peers with larger fixed-cost footprints.
Bears Say
No Revenue / Persistent LossesAbsence of product revenue and continued net losses mean the company is not self-sustaining and must fund operations externally. Over the medium term this elevates execution risk and constrains the ability to invest in multiple programs without additional financing or partnerships.
Negative Shareholder EquityA persistent negative equity position and minimal tangible assets indicate a fragile capital structure. This limits borrowing capacity, raises refinancing and dilution risk, and reduces financial flexibility to withstand clinical setbacks or extend development timelines.
Reliance On External FundingAs a clinical-stage biotech with no commercial sales, operations depend on equity financings, partnerships, or milestone payments. This structural funding reliance increases dilution risk and makes program advancement contingent on successful capital raises or deal-making over the coming months.
BetterLife Pharma News
BETR FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is C$9.71M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Jul 01, 2026 which is in 23 days.
How were BetterLife Pharma’s earnings last quarter?
Currently, no data Available
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 161,787,020 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in TSE:BETR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BetterLife Pharma
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.
Technical Analysis
COSCIENS Biopharma
―
PharmaTher Holdings Ltd
―
Marvel Biosciences Corp
―
Doseology Sciences
―
PharmAla Biotech Holdings, Inc.
―
Options Prices
Currently, No data available
---